+关注
Davidtan0629
暂无个人介绍
IP属地：未知
71
关注
8
粉丝
0
主题
0
勋章
主贴
热门
Davidtan0629
2021-11-12
$Apple(AAPL)$
Free
Davidtan0629
2021-11-12
$Amkor Technology(AMKR)$
okay?
Davidtan0629
2021-11-11
$Apple(AAPL)$
free
Davidtan0629
2021-11-10
$Amkor Technology(AMKR)$
okay?
Davidtan0629
2021-11-09
$Apple(AAPL)$
Free
Davidtan0629
2021-11-09
$Amkor Technology(AMKR)$
okay?
Davidtan0629
2021-11-08
$Amkor Technology(AMKR)$
okay?
Davidtan0629
2021-11-07
$Amkor Technology(AMKR)$
okay?
Davidtan0629
2021-11-06
$Amkor Technology(AMKR)$
Okay
Davidtan0629
2021-11-06
$Apple(AAPL)$
Free
Davidtan0629
2021-11-05
Okay
抱歉，原内容已删除
Davidtan0629
2021-11-05
$Apple(AAPL)$
Free
Davidtan0629
2021-11-05
Okay?
Davidtan0629
2021-11-04
$Apple(AAPL)$
Free
Davidtan0629
2021-11-04
$American Vanguard(AVD)$
Ok
Davidtan0629
2021-11-04
Ok
抱歉，原内容已删除
Davidtan0629
2021-11-04
Ok
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4097843570260640,"uuid":"4097843570260640","gmtCreate":1634741839658,"gmtModify":1635143360652,"name":"Davidtan0629","pinyin":"davidtan0629","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":71,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":879166305,"gmtCreate":1636691625049,"gmtModify":1636691625263,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/b2ea95fe0dc4d24bdae94bf223165770","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879166305","isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879163128,"gmtCreate":1636691375750,"gmtModify":1636691375845,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/2ce3116aa6b4350089cac219494eb25b","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879163128","isVote":1,"tweetType":1,"viewCount":522,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870549748,"gmtCreate":1636638253209,"gmtModify":1636638253348,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>free","text":"$Apple(AAPL)$free","images":[{"img":"https://static.tigerbbs.com/0fa87f4736687b257293ed3505545396","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870549748","isVote":1,"tweetType":1,"viewCount":719,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870026378,"gmtCreate":1636559712222,"gmtModify":1636559712222,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/ad973bdec8d500600f36d8180cfc9f25","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870026378","isVote":1,"tweetType":1,"viewCount":1225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844794297,"gmtCreate":1636458218209,"gmtModify":1636458314541,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/9fec035c7c2f3a91c0c32ec3290603a0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844794297","isVote":1,"tweetType":1,"viewCount":364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844794808,"gmtCreate":1636458194210,"gmtModify":1636458313693,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/802e6ea253bbeee5d32a09f93596940f","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844794808","isVote":1,"tweetType":1,"viewCount":820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845563391,"gmtCreate":1636352069137,"gmtModify":1636352272524,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/b296d20f8b90f6acc0fc3135fae30ad6","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845563391","isVote":1,"tweetType":1,"viewCount":822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845023587,"gmtCreate":1636255086159,"gmtModify":1636255086273,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/af1cdedcb5b54ff460c5934661371810","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845023587","isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842821933,"gmtCreate":1636163416359,"gmtModify":1636163696964,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>Okay","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>Okay","text":"$Amkor Technology(AMKR)$Okay","images":[{"img":"https://static.tigerbbs.com/033b52d3c21cc3916a69ca9a560f5dba","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842821933","isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842867488,"gmtCreate":1636163241751,"gmtModify":1636163684042,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/d67a60cd910e8ef21b04ae677a44b4ea","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842867488","isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846652386,"gmtCreate":1636080271609,"gmtModify":1636080743345,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846652386","repostId":"1128227989","repostType":4,"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846656653,"gmtCreate":1636080241847,"gmtModify":1636080739165,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/4477dd69453f4c2e8bc2616db685ec6f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846656653","isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846658892,"gmtCreate":1636080169281,"gmtModify":1636080380974,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Okay?","listText":"Okay?","text":"Okay?","images":[{"img":"https://static.tigerbbs.com/d3b8a38c328276886fcf41dcc72d5eaa","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846658892","isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848708774,"gmtCreate":1636025819389,"gmtModify":1636025819525,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/fbc90e86e784bd2218754448be60cb4b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848708774","isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848708268,"gmtCreate":1636025788188,"gmtModify":1636025788281,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AVD\">$American Vanguard(AVD)$</a>Ok","listText":"<a href=\"https://laohu8.com/S/AVD\">$American Vanguard(AVD)$</a>Ok","text":"$American Vanguard(AVD)$Ok","images":[{"img":"https://static.tigerbbs.com/d409c2b50b3a6a888bc10f403cdc20ed","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848708268","isVote":1,"tweetType":1,"viewCount":271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848701785,"gmtCreate":1636025698557,"gmtModify":1636025698632,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok ","listText":"Ok ","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848701785","repostId":"1127498048","repostType":4,"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848701529,"gmtCreate":1636025670496,"gmtModify":1636025670585,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848701529","repostId":"1101079537","repostType":4,"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":846652386,"gmtCreate":1636080271609,"gmtModify":1636080743345,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846652386","repostId":"1128227989","repostType":4,"repost":{"id":"1128227989","pubTimestamp":1636067303,"share":"https://www.laohu8.com/m/news/1128227989?lang=&edition=full","pubTime":"2021-11-05 07:08","market":"us","language":"en","title":"S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1128227989","media":"Reuters","summary":" - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.Financials dropped 1","content":"<p>(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p>\n<p>The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.</p>\n<p>Financials dropped 1.3%, most among S&P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p>\n<p>“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p>\n<p>The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p>\n<p>The S&P 500 growth index rose 1.2% while the S&P 500 value index fell 0.5%.</p>\n<p>Among S&P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p>\n<p>Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p>\n<p>The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p>\n<p>Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p>\n<p>“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p>\n<p>“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p>\n<p>Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&P 500 healthcare sector, which fell 0.8%.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p>\n<p>The S&P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p>\n<p>About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq extend record streaks, with boost from chip, growth shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 07:08 GMT+8 <a href=https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".IXIC":"NASDAQ Composite","OEX":"标普100",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","SH":"标普500反向ETF","IVV":"标普500指数ETF","SSO":"两倍做多标普500ETF","SPXU":"三倍做空标普500ETF",".DJI":"道琼斯","OEF":"标普100指数ETF-iShares"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128227989","content_text":"(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.\nThe Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.\nFinancials dropped 1.3%, most among S&P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.\n“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\n“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”\nThe Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.\nThe S&P 500 growth index rose 1.2% while the S&P 500 value index fell 0.5%.\nAmong S&P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.\nQualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.\nThe Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.\n“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.\n“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”\nModerna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&P 500 healthcare sector, which fell 0.8%.\nData showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.\nThe S&P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.\nAbout 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848701529,"gmtCreate":1636025670496,"gmtModify":1636025670585,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848701529","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://www.laohu8.com/m/news/1101079537?lang=&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p>\n<ul>\n <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li>\n</ul>\n<ul>\n <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p>\n<p><i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p>\n<p><i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p>\n<p><i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p>\n<p><i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p>\n<p><i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p>\n<p><i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p>\n<p><b>Updates and recent progress include:</b></p>\n<p><i>COVID-19 Vaccine Development</i></p>\n<ul>\n <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>\n <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>\n <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>\n <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li>\n</ul>\n<p><i>Respiratory Vaccines</i></p>\n<ul>\n <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>\n <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>\n <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li>\n</ul>\n<p><i>Latent Vaccines</i></p>\n<ul>\n <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>\n <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>\n <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li>\n</ul>\n<p><i>Therapeutics</i></p>\n<ul>\n <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>\n <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>\n <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>\n <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>\n <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>\n <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li>\n</ul>\n<p>Moderna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p>\n<p><b>2021 Updated Financial Framework</b></p>\n<ul>\n <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>\n <li></li>\n <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>\n <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>\n <li><b>2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>\n <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>\n <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>\n <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li>\n</ul>\n<p><b>2022 Revenue Drivers</b></p>\n<p>They expect several dynamics will drive 2022 revenues:</p>\n<ul>\n <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>\n <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>\n <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li>\n</ul>\n<p>Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-04 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p>\n<ul>\n <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li>\n</ul>\n<ul>\n <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p>\n<p><i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p>\n<p><i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p>\n<p><i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p>\n<p><i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p>\n<p><i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p>\n<p><i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p>\n<p><b>Updates and recent progress include:</b></p>\n<p><i>COVID-19 Vaccine Development</i></p>\n<ul>\n <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>\n <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>\n <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>\n <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li>\n</ul>\n<p><i>Respiratory Vaccines</i></p>\n<ul>\n <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>\n <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>\n <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li>\n</ul>\n<p><i>Latent Vaccines</i></p>\n<ul>\n <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>\n <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>\n <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li>\n</ul>\n<p><i>Therapeutics</i></p>\n<ul>\n <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>\n <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>\n <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>\n <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>\n <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>\n <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li>\n</ul>\n<p>Moderna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p>\n<p><b>2021 Updated Financial Framework</b></p>\n<ul>\n <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>\n <li></li>\n <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>\n <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>\n <li><b>2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>\n <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>\n <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>\n <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li>\n</ul>\n<p><b>2022 Revenue Drivers</b></p>\n<p>They expect several dynamics will drive 2022 revenues:</p>\n<ul>\n <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>\n <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>\n <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li>\n</ul>\n<p>Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1},"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870549748,"gmtCreate":1636638253209,"gmtModify":1636638253348,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>free","text":"$Apple(AAPL)$free","images":[{"img":"https://static.tigerbbs.com/0fa87f4736687b257293ed3505545396","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870549748","isVote":1,"tweetType":1,"viewCount":719,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848708774,"gmtCreate":1636025819389,"gmtModify":1636025819525,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/fbc90e86e784bd2218754448be60cb4b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848708774","isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879166305,"gmtCreate":1636691625049,"gmtModify":1636691625263,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/b2ea95fe0dc4d24bdae94bf223165770","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879166305","isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879163128,"gmtCreate":1636691375750,"gmtModify":1636691375845,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/2ce3116aa6b4350089cac219494eb25b","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879163128","isVote":1,"tweetType":1,"viewCount":522,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870026378,"gmtCreate":1636559712222,"gmtModify":1636559712222,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/ad973bdec8d500600f36d8180cfc9f25","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870026378","isVote":1,"tweetType":1,"viewCount":1225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842867488,"gmtCreate":1636163241751,"gmtModify":1636163684042,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/d67a60cd910e8ef21b04ae677a44b4ea","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842867488","isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844794297,"gmtCreate":1636458218209,"gmtModify":1636458314541,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/9fec035c7c2f3a91c0c32ec3290603a0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844794297","isVote":1,"tweetType":1,"viewCount":364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844794808,"gmtCreate":1636458194210,"gmtModify":1636458313693,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/802e6ea253bbeee5d32a09f93596940f","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844794808","isVote":1,"tweetType":1,"viewCount":820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845563391,"gmtCreate":1636352069137,"gmtModify":1636352272524,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/b296d20f8b90f6acc0fc3135fae30ad6","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845563391","isVote":1,"tweetType":1,"viewCount":822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845023587,"gmtCreate":1636255086159,"gmtModify":1636255086273,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/af1cdedcb5b54ff460c5934661371810","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845023587","isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842821933,"gmtCreate":1636163416359,"gmtModify":1636163696964,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>Okay","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>Okay","text":"$Amkor Technology(AMKR)$Okay","images":[{"img":"https://static.tigerbbs.com/033b52d3c21cc3916a69ca9a560f5dba","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842821933","isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846656653,"gmtCreate":1636080241847,"gmtModify":1636080739165,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/4477dd69453f4c2e8bc2616db685ec6f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846656653","isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846658892,"gmtCreate":1636080169281,"gmtModify":1636080380974,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Okay?","listText":"Okay?","text":"Okay?","images":[{"img":"https://static.tigerbbs.com/d3b8a38c328276886fcf41dcc72d5eaa","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846658892","isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848708268,"gmtCreate":1636025788188,"gmtModify":1636025788281,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AVD\">$American Vanguard(AVD)$</a>Ok","listText":"<a href=\"https://laohu8.com/S/AVD\">$American Vanguard(AVD)$</a>Ok","text":"$American Vanguard(AVD)$Ok","images":[{"img":"https://static.tigerbbs.com/d409c2b50b3a6a888bc10f403cdc20ed","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848708268","isVote":1,"tweetType":1,"viewCount":271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848701785,"gmtCreate":1636025698557,"gmtModify":1636025698632,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok ","listText":"Ok ","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848701785","repostId":"1127498048","repostType":4,"repost":{"id":"1127498048","pubTimestamp":1636021104,"share":"https://www.laohu8.com/m/news/1127498048?lang=&edition=full","pubTime":"2021-11-04 18:18","market":"us","language":"en","title":"Arhaus Prices IPO At $13/Share, Below Expected Range","url":"https://stock-news.laohu8.com/highlight/detail?id=1127498048","media":"Benzinga","summary":"Home furnishings retailer Arhaus Inc NASDAQARHShas priced its initial public offering (IPO) of 12.9 ","content":"<ul>\n <li>Home furnishings retailer<b> Arhaus Inc</b> NASDAQARHShas priced its initial public offering (IPO) of 12.9 million shares at $13.00 per share.</li>\n <li>The company had expected to price the IPO at $14 -$17 earlier.</li>\n <li>The underwriters will have a 30-day option to purchase up to an additional 1.9 million shares from the company.</li>\n <li>The shares are expected to begin trading on the Nasdaq Global Select Market on Thursday, November 4, 2021, under the ticker symbol \"ARHS.\"</li>\n <li>The offering is expected to close on November 8, 2021, subject to customary closing conditions.</li>\n <li>BofA Securities and Jefferies LLC are acting as joint lead book-running managers and as representatives for the proposed offering.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arhaus Prices IPO At $13/Share, Below Expected Range</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArhaus Prices IPO At $13/Share, Below Expected Range\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-04 18:18 GMT+8 <a href=https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Home furnishings retailer Arhaus Inc NASDAQARHShas priced its initial public offering (IPO) of 12.9 million shares at $13.00 per share.\nThe company had expected to price the IPO at $14 -$17 earlier.\n...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARHS":"Arhaus, Inc."},"source_url":"https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127498048","content_text":"Home furnishings retailer Arhaus Inc NASDAQARHShas priced its initial public offering (IPO) of 12.9 million shares at $13.00 per share.\nThe company had expected to price the IPO at $14 -$17 earlier.\nThe underwriters will have a 30-day option to purchase up to an additional 1.9 million shares from the company.\nThe shares are expected to begin trading on the Nasdaq Global Select Market on Thursday, November 4, 2021, under the ticker symbol \"ARHS.\"\nThe offering is expected to close on November 8, 2021, subject to customary closing conditions.\nBofA Securities and Jefferies LLC are acting as joint lead book-running managers and as representatives for the proposed offering.","news_type":1},"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
